Day: July 23, 2025

Reference is made to IDEX Biometrics ASA’s disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share, split in two tranches. IDEX discloses the following information on behalf of primary insiders.  In tranche 1 of the private placement, total 4,731,594 shares :- CEO and CFO Anders Storbråten, subscribed to 443,616 shares, ISIN NO0013536078, at NOK 3.30 per share, Pinchcliffe AS, a company closely related to Anders Storbråten, subscribed to 295,744 shares, ISIN NO0013536078, at NOK 3.30 per share, andK-konsult AS, a company closely related to chair Morten Opstad, subscribed to 128,156 shares, ISIN NO0013536078, at NOK 3.30 per share. Contact personAnders Storbråten, CEO and CFO Tel: +47 4163 8582E-mail: ir@idexbiometrics.com About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX) is a global technology leader...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) — Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold...

DUBLIN, Ohio, July 22, 2025 (GLOBE NEWSWIRE) — reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), an AI-powered real estate technology company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 14,285,718 shares of its common stock at a purchase price of $0.35 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 14,285,718 shares of common stock at an exercise price of $0.35 per share that are exercisable upon issuance and will expire five years from the effective date of the registration statement covering the resale of the shares of common stock issuable upon exercise of the unregistered warrants. H.C. Wainwright & Co. acted as the exclusive placement agent...